Mukherji, Deborah http://orcid.org/0000-0002-0192-5828
Youssef, Bassem
Dagher, Christelle
El-Hajj, Albert
Nasr, Rami
Geara, Fadi
Rabah, Danny
Al Dousari, Saad
Said, Rabih
Ashou, Raja
Wazzan, Wassim
Jabbour, Michel
Farha, George
Al Hamdani, Nibras
Al Hallaq, Yousuf
Ghazal, Hassan
Dbouk, Haifa
Bachir, Bassel
El Khoury, Clement
Sakr, Ghazi
Hussain, Hero K.
Sayyid, Khaled
Ibrahim, Khaled
Haidar, Mohammad
Zouain, Nicolas
Bitar, Nizar
Alameh, Walid
Abbas, Fadi
Faddoul, Sami
Nemer, Elie
Assaf, Georges
Farhat, Fadi
Bulbul, Muhammad
Temraz, Sally
Shamseddine, Ali
Gillessen, Silke
Omlin, Aurelius
Khauli, Raja
Funding for this research was provided by:
Astellas
Jannsen
Algorithm
Article History
Received: 21 May 2019
Accepted: 4 July 2019
First Online: 11 July 2019
Compliance with ethical standards
:
: D Mukherji: research funding/honoraria from Astellas, Janssen, and Sanofi. A. Shamseddine: research funding/honoraria from Astellas, Janssen, and Sanofi. R. Khauli: research funding/honoraria from Astellas, Janssen, Hickma, and Algorithm. S. Gillessen: advisory role (including IDMCs) and Speakers Bureau: AAA International, Active Biotech, Amgen, Astellas Pharma, Bayer, Bristol-Myers Squibb, CellSearch, Clovis, CureVac, Dendreon, ESSA Pharmaceuticals, Ferring, Innocrin Pharmaceuticals, Janssen Cilag, MaxiVAX SA, Millenium, Nectar, Novartis, Orion, Pfizer, ProteoMediX, Roche, and Sanofi. Co-inventor on patent application (WO 2009138392 A1) for a method for biomarker discover (granted in China, Europe, Japan and the US). Deputy of the ESMO guidelines committee for GU cancers, member of the EAU guideline panel for prostate cancer, past chair of the EORTC GU group. Member of the STAMPEDE trial management group. All the other authors have no relevant conflicts of interest to declare.
: None.